Skip to main content
SpringerLink
Log in

New Developments in the Use of Patient-Reported Outcomes in Cancer Patients Undergoing Immunotherapies

  • Chapter
  • First Online:
Immunotherapy

Part of the book series: Advances in Experimental Medicine and Biology ((AEMB,volume 1244))

Abstract

In a previous chapter, how best to measure symptoms was discussed, the desirable properties of a psychometrically valid symptom assessment tool were listed, available symptom assessment tools were reviewed, methods to assist in the interpretation of patient-reported outcomes (PRO) data were provided, and the current use of PROs in immunotherapy was described. Two areas for further research were also identified. These two areas were (1) deciding on the frequency of administration of symptom assessment and (2) determining the adequacy of the chosen symptom list to cover both known and unknown effects of immunotherapy. This brief update provides new developments on these two critical issues that are of significant concerns to researchers and clinicians who are investigating the use of immunotherapies either singly or in combination in cancer patients.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 189.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Basch E, Iasonos A, McDonough T, Barz A, Culkin A, Kris MG, et al. Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events: results of a questionnaire-based study. Lancet Oncol. 2006;7:903–9.

    Article  Google Scholar 

  2. Basch E. Patient-reported outcomes: an essential component of oncology drug development and regulatory review. Lancet Oncol. 2018;19(5):595–7. https://doi.org/10.1016/S1470-2045(18)30141-4. PubMed PMID: 29726373.

    Article  PubMed  Google Scholar 

  3. Hsu FS, Su CH, Huang KH, et al. J Immunol Res. 2017;2017:6940546. https://doi.org/10.1155/2017/6940546. PubMed PMID: 29376081; PMCID: PMC5742464.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85(5):365–76.

    Article  CAS  Google Scholar 

  5. Cleeland CS, Mendoza TR, Wang XS, et al. Assessing symptom distress in cancer patients: the M. D Anderson Symptom Inventory. Cancer. 2000;89(7):1634–46.

    Article  CAS  Google Scholar 

  6. Dueck AC, Mendoza TR, Mitchell SA, Reeve BB, Castro KM, Rogak LJ, et al. Validity and reliability of the US National Cancer Institute’s patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). JAMA Oncol. 2015;1(8):1051–9.

    Article  Google Scholar 

  7. Mendoza TR, Dueck AC, Bennett AV, Mitchell SA, Reeve BB, Atkinson TM, Li Y, Castro KM, Denicoff A, Rogak LJ, Piekarz RL, Cleeland CS, Sloan JA, Schrag D, Basch E. Evaluation of different recall periods for the US National Cancer Institute’s PRO-CTCAE. Clin Trials. 2017;14(3):255–63. e-Pub 3/2017. PMCID: PMC5448293.

    Article  Google Scholar 

  8. Aloia T, Kim B, Segraves-Chun Y, Cata J, Truty M, Shi Q, Holmes A, Soliz J, Popat K, Rahlfs T, Lee J, Wang X, Morris J, Gottumukkala V, Vauthey J. A randomized controlled trial of postoperative thoracic epidural analgesia versus intravenous patient-controlled analgesia after major hepatopancreatobiliary surgery. Ann Surg. 2017;266:545–54.

    Article  Google Scholar 

  9. Rosenthal DI, Mendoza TR, Fuller CD, Hutcheson KA, Wang XS, Hanna EY, Lu C, Garden AS, Morrison WH, Cleeland CS, Gunn GB. Patterns of symptom burden during radiotherapy or concurrent chemoradiotherapy for head and neck cancer: A prospective analysis using the University of Texas MD Anderson Cancer Center Symptom Inventory-Head and Neck Module. Cancer. 2014;120(13):1975–84. e-Pub 4/2014. PMCID: PMC4095802.

    Article  Google Scholar 

  10. Wang XS, Shi Q, Williams LA, Shah ND, Mendoza TR, Cohen EN, Reuben JM, Cleeland CS, Orlowski RZ. Longitudinal analysis of patient-reported symptoms post-autologous stem cell transplant and their relationship to inflammation in patients with multiple myeloma. Leuk Lymphoma. 2015;56(5):1–7. e-Pub 11/2014. PMCID: PMC4439386.

    Article  Google Scholar 

  11. Willis GB, Reeve BB, Barofsky I. Invited Paper C: The use of cognitive interviewing techniques in quality of life and patient-reported outcomes assessment. In: Lipscomb J, Gotay CC, Snyder C, editors. Outcomes assessment in cancer: measures, methods and applications. Cambridge, UK: Cambridge University Press; 2004. p. 610–22.

    Chapter  Google Scholar 

  12. Hollen PJ, Gralla RJ, Liepa AM, Symanowski JT, Rusthoven JJ. Measuring quality of life in patients with pleural mesothelioma using a modified version of the Lung Cancer Symptom Scale (LCSS): psychometric properties of the LCSS-Meso. Support Care Cancer. 2006;14:11–21. https://doi.org/10.1007/s00520-005-0837-0.

    Article  PubMed  Google Scholar 

  13. Williams LA, Whisenant MS, Mendoza TR, et al. Modification of existing patient-reported outcome measures: qualitative development of the MD Anderson symptom inventory for malignant pleural mesothelioma (MDASI-MPM). Qual Life Res. 2018;27:3229. https://doi.org/10.1007/s11136-018-1982-5.

    Article  PubMed  Google Scholar 

  14. Gelhorn HL, Skalicky AM, Balantac Z, et al. Content validity and electronic PRO (ePRO) usability of the lung cancer symptom scale-mesothelioma (LCSS-Meso) in mesothelioma patients. Support Care Cancer. 2018;26:2229–38. https://doi.org/10.1007/s00520-018-4061-0.

    Article  PubMed  Google Scholar 

  15. Mendoza TR, Wang XS, Williams LA, Shi Q, Vichaya EG, Dougherty PM, Thomas SK, Yucel E, Bastida CC, Woodruff JF, Cleeland CS. Measuring therapy-induced peripheral neuropathy: preliminary development and validation of the Treatment-induced Neuropathy Assessment Scale (TNAS). J Pain. 2015;16(10):1032–43. e-Pub 7/2015. PMCID: PMC4592444.

    Article  Google Scholar 

  16. Williams LA, Garcia-Gonzalez A, Mendoza TR, Haq S, Cleeland CS. Concept domain validation and item generation for the Treatment-Induced Neuropathy Assessment Scale (TNAS). Support Care Cancer. 2018. e-Pub 8/2018. PMID: 30094731.

    Google Scholar 

  17. Basch E, Rogak LJ, Dueck AC. Methods for implementing and reporting patient-reported outcome (PRO) measures of symptomatic adverse events in cancer clinical trials. Clin Ther. 2016;38(4):821–30. https://doi.org/10.1016/j.clinthera.2016.03.011. Epub 2016 Apr 2

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Conflicts of Interest

The author reports no conflict of interest in this work.

Research Funding

This work was supported by grant no. R01 CA242565 from the National Institutes of Health, National Cancer Institute to Tito Mendoza, David Hong and Goldy George. All research at The University of Texas MD Anderson Cancer Center is supported in part by the institution’s Cancer Center Support Grant, NCI P30 CA016672. The content is solely the responsibility of the author and does not necessarily represent the official views of the National Cancer Institute or the National Institutes of Health.

Author information

Authors and Affiliations

  1. Department of Symptom Research, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

    Tito R. Mendoza

Authors
  1. Tito R. Mendoza
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Tito R. Mendoza .

Editor information

Editors and Affiliations

  1. MD Anderson Cancer Center, University of Texas, Houston, TX, USA

    Aung Naing

  2. Baylor College of Medicine, Texas Children’s Hospital, Houston, TX, USA

    Joud Hajjar

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Mendoza, T.R. (2020). New Developments in the Use of Patient-Reported Outcomes in Cancer Patients Undergoing Immunotherapies. In: Naing, A., Hajjar, J. (eds) Immunotherapy. Advances in Experimental Medicine and Biology, vol 1244. Springer, Cham. https://doi.org/10.1007/978-3-030-41008-7_20

Download citation

Publish with us

Policies and ethics

Search

Navigation